These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 39029375)
1. Human translesion DNA polymerases ι and κ mediate tolerance to temozolomide in MGMT-deficient glioblastoma cells. Latancia MT; Leandro GDS; Bastos AU; Moreno NC; Ariwoola AA; Martins DJ; Ashton NW; Ribeiro VC; Hoch NC; Rocha CRR; Woodgate R; Menck CFM DNA Repair (Amst); 2024 Sep; 141():103715. PubMed ID: 39029375 [TBL] [Abstract][Full Text] [Related]
2. Temozolomide resistance mechanisms: unveiling the role of translesion DNA polymerase kappa in glioblastoma spheroids in vitro. Ribeiro DL; Latancia MT; de Souza I; Ariwoola AA; Mendes D; Rocha CRR; Lengert AVH; Menck CFM Biosci Rep; 2024 May; 44(5):. PubMed ID: 38717250 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O Jin L; Kiang KM; Cheng SY; Leung GK Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658 [TBL] [Abstract][Full Text] [Related]
4. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889 [TBL] [Abstract][Full Text] [Related]
5. Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT. Duan C; He B; Wang Y; Liu W; Bao W; Yu L; Xin J; Gui H; Lei J; Yang Z; Liu J; Tao W; Qin J; Luo J; Dong Z Sci Rep; 2024 Aug; 14(1):20199. PubMed ID: 39215105 [TBL] [Abstract][Full Text] [Related]
6. AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage. Huang G; Ouyang M; Xiao K; Zhou H; Zhong Z; Long S; Li Z; Zhang Y; Li L; Xiang S; Ding X Life Sci; 2024 Nov; 357():123111. PubMed ID: 39369843 [TBL] [Abstract][Full Text] [Related]
7. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465 [TBL] [Abstract][Full Text] [Related]
8. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status. Wu Q; Berglund AE; Macaulay RJ; Etame AB Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860 [TBL] [Abstract][Full Text] [Related]
11. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841 [TBL] [Abstract][Full Text] [Related]
12. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma. Tiek DM; Rone JD; Graham GT; Pannkuk EL; Haddad BR; Riggins RB Sci Rep; 2018 May; 8(1):7222. PubMed ID: 29740146 [TBL] [Abstract][Full Text] [Related]
13. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT. Tsai CK; Huang LC; Wu YP; Kan IY; Hueng DY FASEB J; 2019 Dec; 33(12):14171-14184. PubMed ID: 31725331 [TBL] [Abstract][Full Text] [Related]
14. Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O Yousefi Y; Nejati R; Eslahi A; Alizadeh F; Farrokhi S; Asoodeh A; Mojarrad M J Neurooncol; 2024 Aug; 169(1):129-135. PubMed ID: 38762829 [TBL] [Abstract][Full Text] [Related]
15. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma. Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059 [TBL] [Abstract][Full Text] [Related]
16. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance. Li Y; Wang X; Xu T; Xu F; Chen T; Li Z; Wang Y; Chen H; Ming J; Cai J; Jiang C; Meng X Cancer Lett; 2024 Aug; 598():217107. PubMed ID: 38992489 [TBL] [Abstract][Full Text] [Related]
17. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma. Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006 [TBL] [Abstract][Full Text] [Related]
18. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization. Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551 [TBL] [Abstract][Full Text] [Related]
19. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610 [TBL] [Abstract][Full Text] [Related]
20. PDCD10 Is a Key Player in TMZ-Resistance and Tumor Cell Regrowth: Insights into Its Underlying Mechanism in Glioblastoma Cells. Zhu Y; Kim SN; Chen ZR; Will R; Zhong RD; Dammann P; Sure U Cells; 2024 Aug; 13(17):. PubMed ID: 39273014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]